Los Angeles, USA , June 02, 2021 (GLOBE NEWSWIRE) -- Current Therapies and Emerging Drugs in the Prediabetes Pipeline Soon to Boost the Treatment Outlook
Prominent companies such as Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, MicroBiome Therapeutics, and others are developing potential drug candidates to boost the Prediabetes treatment scenario. Out of all the emerging therapies, the late-stage product TOTUM-63 (VALBIOTIS) has shown promising results and will significantly impact the Prediabetes treatment market.
DelveInsight’s “Prediabetes Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the pipeline landscapes. It comprises Prediabetes pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Prediabetes therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prediabetes pipeline products.
Some of the key takeaways from the Prediabetes Pipeline Report
- Notable companies such as Valbiotis, Resverlogix, Caelus Health, SciMar, Boston Therapeutics, MicroBiome Therapeutics, and others are developing potential drug candidates to boost the Prediabetes treatment scenario.
- In February 2020, VALBIOTIS signed a global and long-term partnership with Nestlé Health Science. Under the terms of the deal, VALBIOTIS permits Nestlé Health Science exclusive and global commercial rights to use TOTUM-63 in the prediabetes and Type 2 Diabetes market.
- The patent applications have been filed for TOTUM-63 (VALBIOTIS) in more than 60 countries, including key territories: Europe, the USA, Canada, China, Russia, Japan, Brazil, and Australia. The patent was granted in France in 2014, in the United States in 2018, in Europe in 2019 (39 countries) and Russia in 2020.
- Apabetalone (RVX-208) is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off and returning them to a healthier state. The drug has completed Phase II clinical studies for the treatment of Pre-diabetes.
- Anaerostipes rhamnosivorans by Caelus Health is a newly identified microorganism and is indicated as an intervention in metabolic syndrome. The product is currently in pre-clinical studies for the treatment of Prediabetes.
- SciMar is developing NuPa Renew for people already diagnosed with type 2 diabetes or prediabetes. This pharmaceutical drug will activate the production of hepatic insulin-sensitizing substance (HISS). For some people, NuPa Renew will be able to reverse type 2 diabetes by addressing the underlying biological conditions that led to it.
Get an overview of pipeline landscape @ Prediabetes Clinical Trials Analysis
Prediabetes is a metabolic disorder that is considered a precursor for the development of diabetes mellitus. It is characterised by higher than normal blood glucose levels that have not yet reached diabetic levels.
- Totum-63: VALBIOTIS
TOTUM-63 is a unique and patented combination of 5 plant extracts designed to reduce the risk of developing T2D on prediabetic subjects. TOTUM-63 was developed to challenge perceptions of prediabetes management and help protect the health of prediabetic patients. TOTUM-63 is currently in Phase II/III clinical development program for the Prediabetes treatment.
Research and Development
Phase II/III
NCT02868177: In October 2016, Valbiotis initiated a trial, “Totum-63 Effect on Glucose and Lipid Homeostasis in People With Abdominal Obesity Associated With Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia”. The primary objective of the study was to assess the beneficial effect of Totum-63 compared to a placebo on glucose homeostasis assessed by the fasting plasma glucose level in prediabetics or untreated type 2 diabetics after 24 weeks of consumption. The study got completed in April 2019.
Results:
In July 2019, VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active substance: TOTUM-63), which evaluated this product’s efficacy in a prediabetic population, compared to placebo.
- Eubacterium hallii: Caelus Health
Eubacterium hallii is a microbiota-based dietary supplement currently under clinical intervention in subjects suffering from metabolic syndrome/prediabetes. The product is in Phase II clinical development for the treatment of Prediabetes.
Research and Development
NCT04529473: In August 2020, Caelus Health initiated a trial titled “A Double-blind, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Markers of Glycaemic Control in Healthy Hyperglycaemic Males”. This study aims to evaluate the effect of administration of a next-generation probiotic, Eubacterium hallii, versus placebo on insulin sensitivity and glycemic control, in volunteers with some markers of metabolic syndrome. The trial is currently recruiting with an estimated enrollment of 100 participants and is expected to be completed in January 2022.
For further information, refer to the detailed report @ Prediabetes Pipeline Therapeutics
Scope of Prediabetes Pipeline Drug Insight
- Coverage: Global
- Major Players: 10+ Key Players
- Prominent Players: Valbiotis, Resverlogix, Caelus Health, SciMar, MicroBiome Therapeutics, Boston Therapeutics, and many others.
- Key Drugs Profiles: 10+ Products
- Phases:
- Prediabetes Therapies Late-stage (Phase III)
- Prediabetes Therapies Mid-stage (Phase II)
- Prediabetes Therapies Early-stage (Phase I)
- Prediabetes Pre-clinical stage and Discovery candidates
- Discontinued and Inactive candidates
- Mechanism of Action:
- Extra terminal domain protein inhibitors
- Tumour necrosis factor-alpha inhibitors
- Bromodomain and extra terminal domain protein inhibitors
- Virus internalisation inhibitors
- Gastrointestinal microbiome modulators
- Molecule Types:
- Stem gene therapy
- Bacteria
- Biological
- Route of Administration:
- Oral
- Subcutaneous
- Product Types:
- Monotherapy
- Combination
- Mono/Combination
Key Questions regarding Current Prediabetes Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
- What are the current options for Prediabetes treatment?
- How many companies are developing therapies for the treatment of Prediabetes?
- How many are Prediabetes emerging therapies in the early-stage, mid-stage, and late development stages to treat Prediabetes?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Prediabetes market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Prediabetes?
- What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Prediabetes therapies?
- What are the critical designations that have been granted for the emerging therapies for Prediabetes?
- How many patents are granted and pending for the emerging therapies to treat Prediabetes?
Table of Contents
| 1 | Prediabetes Report Introduction |
| 2 | Prediabetes Executive Summary |
| 3 | Prediabetes Overview |
| 4 | Prediabetes – DelveInsight’s Analytical Perspective In-depth Commercial Assessment |
| 5 | Prediabetes Pipeline Therapeutics |
| 6 | Prediabetes Mid Stage Products (Phase II/III) |
| 6.1 | Totum-63: Valbiotis |
| 7 | Prediabetes Mid Stage Products (Phase II) |
| 7.1 | Apabetalone: Resverlogix |
| 8 | Prediabetes Early Stage Products (Phase I) |
| 8.1 | Drug name: Company name |
| 9 | Prediabetes Preclinical Stage Products |
| 9.1 | Anaerostipes rhamnosivorans: Caelus Health |
| 10 | Prediabetes Therapeutic Assessment |
| 11 | Prediabetes Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Prediabetes Key Companies |
| 14 | Prediabetes Key Products |
| 15 | Prediabetes Unmet Needs |
| 16 | Prediabetes Market Drivers and Barriers |
| 17 | Prediabetes Future Perspectives and Conclusion |
| 18 | Prediabetes Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
Get a customised pipeline report @ Prediabetes Drugs Pipeline Report
Related Reports
DelveInsight's Prediabetes - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Prediabetes - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Prediabetes in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's "Multiple Organ Dysfunction Syndrome Market Report 2030" delivers an in-depth understanding, historical and forecasted epidemiology, market trends in the 7MM.
DelveInsight's Corneal Endothelial Dystrophy - Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
DelveInsight's Onychomycosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an overview and an understanding of historical and forecasted epidemiology.
DelveInsight's Deep Vein Thrombosis Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology in 7MM.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.